These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 26344623)

  • 1. HIV DNA Vaccine: Stepwise Improvements Make a Difference.
    Felber BK; Valentin A; Rosati M; Bergamaschi C; Pavlakis GN
    Vaccines (Basel); 2014 May; 2(2):354-79. PubMed ID: 26344623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.
    Elizaga ML; Li SS; Kochar NK; Wilson GJ; Allen MA; Tieu HVN; Frank I; Sobieszczyk ME; Cohen KW; Sanchez B; Latham TE; Clarke DK; Egan MA; Eldridge JH; Hannaman D; Xu R; Ota-Setlik A; McElrath MJ; Hay CM;
    PLoS One; 2018; 13(9):e0202753. PubMed ID: 30235286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA/MVA Vaccines for HIV/AIDS.
    Iyer SS; Amara RR
    Vaccines (Basel); 2014 Feb; 2(1):160-78. PubMed ID: 26344473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin.
    McCoy JR; Mendoza JM; Spik KW; Badger C; Gomez AF; Schmaljohn CS; Sardesai NY; Broderick KE
    Hum Vaccin Immunother; 2014; 10(10):3039-47. PubMed ID: 25483486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electroporation-based DNA immunisation: translation to the clinic.
    Luxembourg A; Evans CF; Hannaman D
    Expert Opin Biol Ther; 2007 Nov; 7(11):1647-64. PubMed ID: 17961089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin.
    McCoy JR; Mendoza JM; Spik KW; Badger C; Gomez AF; Schmaljohn CS; Sardesai NY; Broderick KE
    Hum Vaccin Immunother; 2015; 11(3):746-54. PubMed ID: 25839221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent immune responses induced by a human immunodeficiency virus DNA vaccine delivered in association with electroporation in the skin of nonhuman primates.
    Martinon F; Kaldma K; Sikut R; Culina S; Romain G; Tuomela M; Adojaan M; Männik A; Toots U; Kivisild T; Morin J; Brochard P; Delache B; Tripiciano A; Ensoli F; Stanescu I; Le Grand R; Ustav M
    Hum Gene Ther; 2009 Nov; 20(11):1291-307. PubMed ID: 19627235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques.
    Luckay A; Sidhu MK; Kjeken R; Megati S; Chong SY; Roopchand V; Garcia-Hand D; Abdullah R; Braun R; Montefiori DC; Rosati M; Felber BK; Pavlakis GN; Mathiesen I; Israel ZR; Eldridge JH; Egan MA
    J Virol; 2007 May; 81(10):5257-69. PubMed ID: 17329330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic and prophylactic DNA vaccines for HIV-1.
    Ramirez LA; Arango T; Boyer J
    Expert Opin Biol Ther; 2013 Apr; 13(4):563-73. PubMed ID: 23477730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8
    Li SS; Kochar NK; Elizaga M; Hay CM; Wilson GJ; Cohen KW; De Rosa SC; Xu R; Ota-Setlik A; Morris D; Finak G; Allen M; Tieu HV; Frank I; Sobieszczyk ME; Hannaman D; Gottardo R; Gilbert PB; Tomaras GD; Corey L; Clarke DK; Egan MA; Eldridge JH; McElrath MJ; Frahm N;
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28931520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques.
    Hirao LA; Wu L; Khan AS; Satishchandran A; Draghia-Akli R; Weiner DB
    Vaccine; 2008 Jan; 26(3):440-8. PubMed ID: 18082294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
    Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
    PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation.
    Otten GR; Schaefer M; Doe B; Liu H; Megede JZ; Donnelly J; Rabussay D; Barnett S; Ulmer JB
    Vaccine; 2006 May; 24(21):4503-9. PubMed ID: 16181711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.
    Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo PO; Khamboonruang C; Nelson KE
    AIDS; 1995 Sep; 9(9):1079-83. PubMed ID: 8527082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
    Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
    PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo.
    Widera G; Austin M; Rabussay D; Goldbeck C; Barnett SW; Chen M; Leung L; Otten GR; Thudium K; Selby MJ; Ulmer JB
    J Immunol; 2000 May; 164(9):4635-40. PubMed ID: 10779767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
    Jiang W; Ren L; Jin N
    J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation.
    Dolter KE; Evans CF; Ellefsen B; Song J; Boente-Carrera M; Vittorino R; Rosenberg TJ; Hannaman D; Vasan S
    Vaccine; 2011 Jan; 29(4):795-803. PubMed ID: 21094270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene.
    Zhang X; Divangahi M; Ngai P; Santosuosso M; Millar J; Zganiacz A; Wang J; Bramson J; Xing Z
    Vaccine; 2007 Jan; 25(7):1342-52. PubMed ID: 17052817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.
    Ake JA; Schuetz A; Pegu P; Wieczorek L; Eller MA; Kibuuka H; Sawe F; Maboko L; Polonis V; Karasavva N; Weiner D; Sekiziyivu A; Kosgei J; Missanga M; Kroidl A; Mann P; Ratto-Kim S; Anne Eller L; Earl P; Moss B; Dorsey-Spitz J; Milazzo M; Laissa Ouedraogo G; Rizvi F; Yan J; Khan AS; Peel S; Sardesai NY; Michael NL; Ngauy V; Marovich M; Robb ML
    J Infect Dis; 2017 Nov; 216(9):1080-1090. PubMed ID: 28968759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.